COGT
Cogent Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Buy"
MACD Death Cross
Bearish Engulfing
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About COGT
Cogent Biosciences, Inc.
A biotechnology company that focused on developing novel precision immunotherapies to treat cancer
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451
--
Cogent Biosciences, Inc., was founded in Delaware. The company is a biotechnology company that develops precision therapies for genetic diseases. Cogent's most advanced product, PLX 9486, is a highly selective tyrosine kinase inhibitor designed to effectively inhibit KIT D816V mutations and other mutations in KIT exon 17. KITD816V can cause a rare and serious disease called systemic mastocytosis.
Company Financials
EPS
COGT has released its 2025 Q2 earnings. EPS was reported at -0.59, versus the expected -0.58, missing expectations. The chart below visualizes how COGT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
